Canaccord Genuity reiterated their buy rating on shares of Quanterix (NASDAQ:QTRX) in a research report report published on Thursday, AnalystRatings.com reports. Canaccord Genuity currently has a $35.00 price target on the stock.
Other equities analysts have also recently issued research reports about the stock. Zacks Investment Research raised shares of Quanterix from a hold rating to a buy rating and set a $24.00 price target on the stock in a research report on Wednesday, October 9th. BTIG Research set a $35.00 target price on shares of Quanterix and gave the stock a buy rating in a research report on Wednesday, August 7th. Finally, ValuEngine cut shares of Quanterix from a buy rating to a hold rating in a research report on Tuesday, August 6th.
NASDAQ QTRX traded down $1.08 during trading hours on Thursday, hitting $22.33. The company’s stock had a trading volume of 12,446 shares, compared to its average volume of 158,341. Quanterix has a 52 week low of $16.00 and a 52 week high of $36.15. The company has a market capitalization of $511.36 million, a PE ratio of -15.62 and a beta of 1.25. The company has a current ratio of 5.43, a quick ratio of 4.91 and a debt-to-equity ratio of 0.10. The company’s 50-day simple moving average is $21.67 and its two-hundred day simple moving average is $26.06.
In related news, Director Marijn E. Dekkers sold 89,759 shares of Quanterix stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $13.63, for a total value of $1,223,415.17. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP David C. Duffy sold 1,667 shares of Quanterix stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $19.88, for a total transaction of $33,139.96. Insiders sold a total of 101,981 shares of company stock worth $1,519,894 in the last ninety days. 30.80% of the stock is currently owned by insiders.
Several large investors have recently bought and sold shares of QTRX. Carnegie Capital Asset Management LLC purchased a new position in shares of Quanterix during the 2nd quarter valued at $845,000. Steward Partners Investment Advisory LLC purchased a new position in shares of Quanterix during the 2nd quarter valued at $76,000. TD Asset Management Inc. grew its position in shares of Quanterix by 1.2% during the 2nd quarter. TD Asset Management Inc. now owns 49,700 shares of the company’s stock valued at $1,679,000 after purchasing an additional 600 shares in the last quarter. Candriam Luxembourg S.C.A. grew its position in shares of Quanterix by 100.0% during the 2nd quarter. Candriam Luxembourg S.C.A. now owns 24,000 shares of the company’s stock valued at $807,000 after purchasing an additional 12,000 shares in the last quarter. Finally, Swiss National Bank purchased a new position in shares of Quanterix during the 2nd quarter valued at $558,000. 61.37% of the stock is currently owned by institutional investors.
Quanterix Company Profile
Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Simoa HD-1 instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids.
Featured Article: Asset Allocation Models, Which is Right For You?
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.